Sanmina Corp. Hits New 52-Week High, Surging 319.6% in Value

Sanmina Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 278.87 on June 2, 2026. This achievement underscores the company's robust performance, with a remarkable one-year return of 319.6%, significantly outpacing the S&P 500's 28.2% gain during the same period. The company has demonstrated strong financial health, highlighted by a net profit growth of 90.01% reported on March 26, alongside impressive operating cash flow of USD 977.35 million and net sales reaching USD 4,013.27 million. Sanmina's return on equity stands at 12.64%, reflecting effective management efficiency, while its price-to-book ratio of 4.95 indicates a fair valuation compared to industry peers. Additionally, the company maintains a low debt-to-equity ratio of 0.31 and has been net-debt free, further solidifying its financial stability. Promoter confidence is also on the rise, with a 2.11% increase in stake over the previous quarter, signaling a positive outlook for the company's future.